Abstract: The present invention provides peptoid polymers capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids comprising the peptoid polymers provided herein. The peptoid polymers and peptoid-peptide hybrids provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.
Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
June 23, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
Abstract: The present disclosure provides methods for capturing recombinant collagen 7 from cell culture and methods of purifying recombinant collagen 7. Also provided are compositions comprising purified recombinant collagen 7 that may be used for administration to humans.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
June 2, 2020
Assignee:
PHOENIX TISSUE REPAIR, INC.
Inventors:
Igor Quinones-Garcia, Benjamin Simeone, Raymond Lillie, Ting Yang, David Nichols
Abstract: The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partne
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
June 2, 2020
Assignee:
Cell Signaling Technology, Inc.
Inventors:
Albrecht Moritz, John Edward Rush, II, Roberto Polakiewicz
Abstract: The invention provides cell-permeable Ga-Interacting Vesicle associated protein (GIV)-derived peptides and their use for treatment of diverse diseases. The invention further provides C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT)-based peptides and GIV-CT encoding vectors and methods of use thereof, for successfully manipulating the diverse pathophysiologic processes in which GIV has been implicated. In one aspect, the invention provides cell-permeable peptides PTD-GIV-CT comprising (i) a peptide transduction domain (PTD) and (ii) a C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT) or a mutant thereof. In one embodiment, said peptides are capable of activating Gi downstream of receptor tyrosine kinases (RTKs). The invention also provides pharmaceutical compositions comprising one or more of the peptides of the invention as well as vectors encoding such peptides.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
May 19, 2020
Assignee:
The Regents of the University of California
Abstract: A set of cationic amphiphilic self-assembled peptides (CASPs) is presented that employ high-charge density at fiber edges to disrupt bacterial membranes. CASP nanofibers are effective against Pseudomonas biofilms. There is an inherent trade-off between the ability of the peptides to undergo nanofibrous self-assembly and having a high terminal charge density required for effective bactericidal efficacy. The self-assembled peptide hydrogel presented achieves a balance of these opposing factors. Also demonstrated is the applicability of the new composition in an injectable hydrogel formulation. A CASP platform may be useful for topical application and integration into medical coatings, grafts, devices, and prostheses, thereby reducing risk of bacterial infection and related failure.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
April 28, 2020
Assignee:
New Jersey Institute of Technology
Inventors:
Vivek A. Kumar, Peter Nguyen, Biplab Sarkar, Shivani Jaisinghani
Abstract: This present application relates to a drug delivery method. In particular, the present invention discloses a non-invasive drug delivery method using Listeria adhesion protein (LAP) an analogue, or a fragment thereof. Incorporation of those peptides or a fragment thereof, either by a physical mixture of a pharmaceutical formulation or as a covalent construction at a molecular level or nanoscale is within the scope of this disclosure.
Type:
Grant
Filed:
October 4, 2018
Date of Patent:
April 28, 2020
Assignee:
Purdue Research Foundation
Inventors:
Arun K. Bhunia, Rishi Drolia, Manalee Samaddar
Abstract: The present invention provides a peptide composition that can achieve both excellent storage stability and transparency. The peptide composition of the present invention includes: a self-assembling peptide; a buffering agent having a pKa of 3.5 or more and less than 7.5 and containing one or more nitrogen atoms; and water, and has a pH of from 4.5 to 6.6.
Abstract: A method of treatment of pain in a person with a D peptide chemokine receptor antagonist (CRA), and a pharmaceutically acceptable carrier is disclosed. Because chemokines desensitize opiate receptors and enhance the perception of pain said D-peptide CRA, given with a suboptimal dose of an opioid, such as morphine, will restore opioid analgesic efficacy by blocking the cognate chemokine ligand from binding to its receptor and desensitizing the opioid receptor. This strategy of combining a suboptimal dose of morphine with a CRA enhances the potency of morphine, permitting use of lower doses of morphine to obtain equivalent and near maximal analgesia. Lower morphine (opioid) doses have less risk of adverse effects, and potentially also of development of tolerance and dependence.
Abstract: Methods are provided for quantifying the cyclin-dependent kinase inhibitor 2A protein (p16) p16 protein directly in biological samples that have been fixed in formalin by SRM/MRM mass spectrometry. A protein sample is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and the p16 protein is quantitated in the resulting sample by quantitating in the protein sample at least one fragment peptide from p16. Peptides can be quantitated in modified or unmodified form. An example of a modified form of a p16 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
Type:
Grant
Filed:
September 10, 2018
Date of Patent:
April 14, 2020
Assignee:
NantOmics, LLC
Inventors:
David B. Krizman, Todd Hembrough, Eunkyung An
Abstract: The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.
Type:
Grant
Filed:
August 25, 2016
Date of Patent:
March 17, 2020
Assignee:
Roseman University of Health Sciences
Inventors:
Thuc T. Le, Yasuyo Urasaki, Ronald R. Fiscus
Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
Abstract: The present disclosure provides oleanoyl tripeptide to prevent skin aging. More specifically the invention discloses the anti-collagenase, anti-elastase, enhancement of TGF-? secretion in fibroblasts, UV protection, oxidative stress protection, and other properties of the oleanoyl-KVK tripeptide which aids in preventing skin aging.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
March 17, 2020
Assignee:
SAMI LABS LIMITED
Inventors:
Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Rajendran Ramanujam
Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.
Type:
Grant
Filed:
January 17, 2018
Date of Patent:
March 17, 2020
Assignee:
PFIZER INC.
Inventors:
Debra D. Pittman, Rodney M. Camire, Joachim Fruebis
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
Type:
Grant
Filed:
September 22, 2016
Date of Patent:
March 10, 2020
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
Abstract: [Problem] To provide a highly safe and efficacious antitumor agent that is derived from probiotics. [Solution] The present invention relates to an antitumor agent comprising a compound represented by formula (1) or a complex thereof as an active ingredient. In formula (1): R1 represents a hydrogen atom or a hydroxymethyl group; R2 represents a hydrogen atom, a methyl group or a hydroxymethyl group; and R3, R4 and R5 each independently represent a methyl group, an N5-(trans-5-hydroxy-3-methylpent-2-enoyl) group, an N5-(cis-5-hydroxy-3-methylpent-2-enoyl) group or an N5-(trans-4-carboxy-3-methylpent-2-enoyl) group. According to the present invention, a highly safe and efficacious antitumor agent can be provided.
Type:
Grant
Filed:
January 19, 2017
Date of Patent:
March 3, 2020
Assignee:
National University Corporation Asahikawa Medical University
Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.
Abstract: The present invention relates to a novel use of proline containing dipeptides for the prevention and/or treatment of skin conditions associated with altered, damaged or malfunctioning sebaceous glands.